Tislelizumab,Sorafenib
BeiGene,Novartis
['ca,022,i', 'rationale-301', 'aster,70', 'ca,022,1', 'io,108,cl,01', 'hcc', 'sorafenib', 'tislelizumab', 'emergent ']
tislelizumab versus sorafenib as 1st line treatment for hcc : rationale-301 age 65 years subgroup at at #wcgic2023 by elderly pts: less advanced stage, fewer hbv, most pts from europe/us higher efficacy for tislelizumab vs sora &amp; less tox 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology